SCLC Tarlatamab Blood Collection

Analysis of Blood Samples in Small Cell Lung Cancer Patients Treated With Tarlatamab

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07468656

Enrollment

Registered

2026-03-12

Start date

2026-10-01

Completion date

2028-12-01

Last updated

2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small-cell Lung Cancer

Brief summary

The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting. The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor * Appropriate candidate for treatment with tarlatamab based on investigator discretion * Age \> 18 years * Signed written informed consent including HIPAA according to institutional guidelines

Exclusion criteria

* Does not meet all inclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Number of blood samples collected to better characterize tarlatamab in real-world setting	Days 1, 8, and 15 of tarlatamab and after each interval scan for disease assessment	Studies to better understand tarlatamab may include, but are not limited to, the following: 1) predictors of response to treatment with tarlatamab, 2) identification of predictive biomarkers for the development of cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS), 3) characterization of the immune cell environment induced by tarlatamab, 4) identification of resistance mechanisms to tarlatamab treatment, and 5) development of potential translational correlates.

Contacts

CONTACTLaura Alder, MD

laura.alder@duke.edu+1 919 862 5400

PRINCIPAL_INVESTIGATORLaura Alder, MD

Duke Health

Outcome results